United States - English - NLM (National Library of Medicine)

northstar rxllc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate is indicated in adult and pediatric patients for the: limitations of use hydroxychloroquine sulfate is not recommended for: for the most current information about drug resistance, refer to the latest recommendations from the center for disease control and prevention.1 hydroxychloroquine sulfate is indicated for the treatment of acute and chronic rheumatoid arthritis in adults. hydroxychloroquine sulfate is indicated for the treatment of systemic lupus erythematosus in adults. hydroxychloroquine sulfate is indicated for the treatment of chronic discoid lupus erythematosus in adults. hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to hydroxychloroquine sulfate during pregnancy. encourage patients to register by contacting 1-877-311-8972. risk summary prolonged clinical experience over decades of use an

United States - English - NLM (National Library of Medicine)

sandoz inc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate is indicated in adult and pediatric patients for the: limitations of use hydroxychloroquine sulfate is not recommended for: for the most current information about drug resistance, refer to the latest recommendations from the center for disease control and prevention1. hydroxychloroquine sulfate is indicated for the treatment of acute and chronic rheumatoid arthritis in adults. hydroxychloroquine sulfate is indicated for the treatment of systemic lupus erythematosus in adults. hydroxychloroquine sulfate is indicated for the treatment of chronic discoid lupus erythematosus in adults. hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to hydroxychloroquine sulfate during pregnancy. encourage patients to register by contacting 1-877-311-8972. risk summary prolonged clinical experience over decades of use a

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablet in indicated in adult and pediatric patients for the: limitations of use: hydroxychloroquine sulfate tablet is not recommended for: for the most current information about drug resistance, refer to the latest recommendations from the center for disease control and prevention1 . hydroxychloroquine sulfate tablet is indicated for the treatment of acute and chronic rheumatoid arthritis in adults. hydroxychloroquine sulfate tablet is indicated for the treatment of systemic lupus erythematosus in adults. hydroxychloroquine sulfate tablet is indicated for the treatment of chronic discoid lupus erythematosus in adults. hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to hydroxychloroquine sulfate during pregnancy. encourage patients to register by contacting 1-877-311-8972. risk summary prolonged clin

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax. hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria: prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the centers for disease control and prevention (cdc) malaria website (http://www.cdc.gov/malaria). hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. use of hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablets are not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology (12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax and p. ovale infections, concomitant therapy with an 8-aminoquinoline drug

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablet in indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablet is not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology (12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax and p. ovale infections, concomitant therapy with an 8-aminoquinoline dr

United States - English - NLM (National Library of Medicine)

american health packaging - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablet in indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablet is not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology (12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax and p. ovale infections, conc

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablet in indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablet is not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology ( 12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active agai

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablet in indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablet is not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology (12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax and p. ovale infections, concomitant therapy with an 8-aminoquinoline dr

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets is indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablets is not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology (12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax and p. ovale infections, concomitant therapy with an 8-aminoquinoline drug i